Diffuse Alveolar Hemorrhage as a Life-Threatening Feature of Juvenile Onset Systemic Lupus Erythematosus: A Case-Based Review.

Autor:	Kasap-Demir B; Department of Pediatrics Division of Nephrology & Rheumatology, İzmir Katip Çelebi University, İzmir, Turkey.; Department of Pediatrics, Health Sciences University İzmir Tepecik Training and Research Hospital, İzmir, Turkey., Bayram G; Department of Pediatrics, Health Sciences University İzmir Tepecik Training and Research Hospital, İzmir, Turkey., Önder-Siviş Z; Division of Hematology, Health Sciences University İzmir Tepecik Training and Research Hospital Department of Pediatrics, İzmir, Turkey., Güneş-Tatlı B; Division of Hematology, Health Sciences University İzmir Tepecik Training and Research Hospital Department of Pediatrics, İzmir, Turkey., Anıl BA; Department of Pediatrics, Health Sciences University İzmir Tepecik Training and Research Hospital, İzmir, Turkey.; Department of Pediatrics Division of Pediatric Intensive Care, İzmir Katip Çelebi University, İzmir, Turkey.
Jazyk:	angličtina
Zdroj:	Mediterranean journal of rheumatology [Mediterr J Rheumatol] 2022 Mar 31; Vol. 33 (1), pp. 81-87. Date of Electronic Publication: 2022 Mar 31 (Print Publication: 2022).
DOI:	10.31138/mjr.33.1.81
Abstrakt:	Diffuse alveolar hemorrhage is an uncommon but serious complication of systemic lupus erythematosus (SLE). We reported a 17-year-old boy with idiopathic thrombocytopenic purpura, who admitted with pallor and petechiae. He had Coombs positive hemolytic anemia and thrombocytopenia (hemoglobin 6.2g/dL, platelets 10,000/mm 3 and lactate dehydrogenase 1024U/L), cough, tachypnea, and desaturation in the room air. Chest radiograph revealed bilateral diffuse alveolar opacities and computed tomography showed bilateral diffuse alveolar infiltrates and ground-glass opacity consistent with pulmonary hemorrhage. Anti-nuclear antibody (ANA) was 1:640 with positive Ro and anti-phospholipid antibodies, low C3 and C4, but negative anti-double-stranded DNA. He was treated with pulse methylprednisolone followed by tapering doses of steroids and with 6 doses of intravenous cyclophosphamide once every two weeks followed by mycophenolate mofetil. He had no relapse in the following 3 years. The case was reported to emphasise this life-threatening complication of juvenile-onset SLE and we reviewed the literature. (© 2022 The Mediterranean Journal of Rheumatology (MJR).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu